Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTHrP neutralizing antibody
- Development stage
- Unknown
- Lead developer
- BioGate Precision Medicine
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PTHrP neutralizing antibodies are a class of monoclonal antibodies designed to bind and neutralize parathyroid hormone-related protein (PTHrP). PTHrP is a tumor-derived factor that is frequently overexpressed in various solid tumors, including pancreatic, lung, breast, and head and neck cancers. It plays a critical role in driving tumor progression, osteolytic bone metastasis, cancer cachexia (including adipose tissue browning and muscle wasting), and humoral hypercalcemia of malignancy (HHM). By binding to the N-terminal region of PTHrP, these neutralizing antibodies block its interaction with the parathyroid hormone 1 receptor (PTH1R), thereby inhibiting downstream signaling cascades. Clinical-stage candidates in this class include BGM-2121, developed by BioGate Precision Medicine, which is currently being evaluated in Phase I clinical trials for advanced solid tumors.
- Other names
- anti-PTHrP antibodyanti-PTHrP monoclonal antibodyanti-parathyroid hormone-related protein antibodyanti-parathyroid hormone-related protein monoclonal antibodyPTHrP antibodyPTHrP-neutralizing antibody
Beyond the preview
Go deeper on PTHrP neutralizing antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTHrP neutralizing antibody.